Avid Bioservices Inc (CDMO)

[biopharm]

Nikoletta L. Kallinteris 1, Thomas O. Kleen 2, Min Tang 1, Shen Yin 1, Tobi Guennel 3, Jennifer Lai 1, Victor Nowakowski 2, Steven Olek 2, Steve King 1, Joseph S. Shan 1
1 Peregrine Pharmaceuticals
2 Epiontis GmbH, Berlin, Germany
3 Precision Medicine, Frederick MD
SITC’17 #P87 ABSTRACT:
BACKGROUND
SUNRISE (NCT01999673 ...
...

That is a must read post for anyone who has not read it yet...and thanks CJ!

An amazing set of data looks to be presenting this weekend and how often that you have a few companies such as above and the streak continues where those collaborators with Peregrine seem to attract much attention....in this case Bird&Bird advised Precision For Medicine to move ahead with a buyout of Epiontis and a show of hands that believe it is ALL to do with PS Targeting data that has extracted some statistically significant and powerful Biomarkers that will become very valuable to BPs that want to be able to stop trials successfully early, based on the Biomarkers that were discovered (new knowledge based on PS Targeting data...)

Epiontis info
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134746427

Digging deeper...
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134747702

-----

...Bird & Bird advises Precision Medicine Group on the acquisition of Epiontis
09 October 2017

Bird & Bird LLP advises Precision Medicine Group, a scientific services company helping life science innovators develop medical products, on the acquisition of all shares in Epiontis GmbH, a leading immune monitoring and epigenetic technology service provider based in Berlin.

The acquisition will allow Precision for Medicine to expand on its immune monitoring capabilities with Epiontis’s epigenetic technology, and strengthen its global footprint in the rapidly expanding precision medicine sector.

The Bird & Bird team advised Precision for Medicine on the due diligence, signing and closing of the transaction, including IP patent due diligence and regulatory advice regarding the life sciences aspects of the deal.
..


https://investorshub.advfn.com/boards/read_msg.aspx?message_id=135546947